{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:52:50Z","timestamp":1783367570477,"version":"3.54.6"},"reference-count":31,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The current study investigated the superiority of anxiolytic effects of venlafaxine extended release (ER) compared with placebo and its safety and tolerability in Japanese adult outpatients with generalized anxiety disorder (GAD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this placebo\u2010controlled, double\u2010blind study, 357 eligible participants were randomized to receive venlafaxine ER (75\u2013225 mg\/day) or placebo for 8\u2009weeks. The primary endpoint was change from baseline to week 8 in Hamilton Anxiety Rating Scale (HAM\u2010A) total score. Secondary endpoints included changes from baseline to week 8 in scores of HAM\u2010A psychic anxiety factors, HAM\u2010A somatic anxiety factors, Clinical Global Impressions\u2010Severity of Illness (CGI\u2010S), Generalized Anxiety Disorder\u20107 (GAD\u20107), Zung Self\u2010Rating Anxiety Scale (Z\u2010SAS), Sheehan Disability Scale (SDS), and the absolute score of Clinical Global Impressions\u2010Global Improvement (CGI\u2010I).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Venlafaxine ER showed statistically significant reduction in HAM\u2010A total score at week 8 (difference versus placebo:\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.012). The results of all secondary endpoints were consistent with this finding and likewise demonstrated statistical significance in favor of venlafaxine ER in investigator\u2010 and patient\u2010rated scales. Venlafaxine ER further showed statistically significant remission in total HAM\u2010A score. These results showed that venlafaxine ER improved patients' functional disabilities along with symptoms more than placebo. Venlafaxine ER was well tolerated, and safety findings were generally consistent with the known safety profile of the drug.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Venlafaxine ER has a favorable benefit\u2013risk profile in adult Japanese patients with GAD, indicating its potential to improve GAD symptoms as well as patients' function and exert superior anxiolytic effects over placebo without any new safety concern.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>Japan Registry of Clinical Trials Identifier jRCT2031220156.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/pcn.13907","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:59:53Z","timestamp":1761137993000},"page":"849-858","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A randomized, double\u2010blinded, placebo\u2010controlled study to evaluate the efficacy and safety of venlafaxine extended release in\n                    <scp>Japanese<\/scp>\n                    patients with generalized anxiety disorder"],"prefix":"10.1111","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0321-1714","authenticated-orcid":false,"given":"Tempei","family":"Otsubo","sequence":"first","affiliation":[{"name":"Department of Psychosomatic and Psychiatric Medicine Tokyo Women's Medical University Adachi Medical Center  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0736-7070","authenticated-orcid":false,"given":"Koichiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry Kyorin University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Sapporo Hanazono Hospital  Sapporo Japan"},{"name":"Department of Psychiatry Tokyo Medical University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ataru","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Aoyama Gakuin University Department of Education, College of Education, Psychology and Human Studies\/Health Administration Center  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7469-2922","authenticated-orcid":false,"given":"Keisuke","family":"Nomoto","sequence":"additional","affiliation":[{"name":"Medical Affairs Viatris Pharmaceuticals Japan G.K  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Higa","sequence":"additional","affiliation":[{"name":"Medical Affairs Viatris Pharmaceuticals Japan G.K  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Asami","sequence":"additional","affiliation":[{"name":"Medical Affairs Viatris Pharmaceuticals Japan G.K  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Sun","sequence":"additional","affiliation":[{"name":"Biometrics, Data Management and Programming Viatris Inc.  Canonsburg Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Marschall","sequence":"additional","affiliation":[{"name":"Global Clinical Sciences, Meda Pharma GmbH &amp; Co. KG (a Viatris company)  Bad Homburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2017.19.2\/macrocq"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2211767"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787"},{"key":"e_1_2_9_5_1","first-page":"157","article-title":"Generalized anxiety disorder and panic disorder in adults","volume":"106","author":"DeGeorge KC","year":"2022","journal-title":"Am. Fam. Physician"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-021-03363-3"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S456272"},{"key":"e_1_2_9_8_1","unstructured":"National Institute for Health and Care Excellence.Generalised anxiety disorder and panic disorder in adults. Updated 15 June 2020. Accessed February 18 2025. Available from:https:\/\/www.nice.org.uk\/guidance\/cg113."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-14-S1-S1"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S456276"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.6.968"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0805"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(03)00046-4"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.179.1.15"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.23.3082"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_9_19_1","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","author":"Guy W","year":"1976"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_2_9_22_1","first-page":"22","article-title":"The Mini\u2010international neuropsychiatric interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM\u2010IV and ICD\u201010","volume":"59","author":"Sheehan DV","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(71)71479-0"},{"key":"e_1_2_9_24_1","first-page":"151","volume-title":"The Anxiety Disease and how to Overcome it","author":"Sheehan DV","year":"1983"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02849.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028140"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.5.503"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20642"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.04.013"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2008.10.4\/kkelly"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0120-8"}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.13907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T11:08:46Z","timestamp":1765192126000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pcn.13907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/pcn.13907"],"URL":"https:\/\/doi.org\/10.1111\/pcn.13907","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"2025-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}